Rallybio Corporation
RLYB · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 0% | 0% | 457.9% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 21.1% |
| R&D Expenses | $4 | $6 | $6 | $7 |
| G&A Expenses | $3 | $4 | $4 | $4 |
| SG&A Expenses | $3 | $4 | $4 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $7 | $10 | $10 | $12 |
| Operating Income | -$7 | -$10 | -$10 | -$12 |
| % Margin | -3,266.5% | -4,743.9% | -4,561.3% | -30,547.4% |
| Other Income/Exp. Net | $23 | $0 | $0 | $1 |
| Pre-Tax Income | $16 | -$10 | -$9 | -$11 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | $16 | -$10 | -$9 | -$11 |
| % Margin | 7,554.7% | -4,576.9% | -4,452.4% | -29,063.2% |
| EPS | 0.36 | -0.22 | -0.21 | -0.25 |
| % Growth | 263.6% | -4.8% | 16% | – |
| EPS Diluted | 0.36 | -0.22 | -0.21 | -0.25 |
| Weighted Avg Shares Out | 45 | 45 | 45 | 45 |
| Weighted Avg Shares Out Dil | 45 | 45 | 45 | 45 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $1 | $1 | $1 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | $16 | -$10 | -$10 | -$12 |
| % Margin | 7,571.2% | -4,731.6% | -4,548.1% | -30,468.4% |